Ying Ou, PhD
About Ying Ou, PhD
Ying Ou, PhD, is the Executive Director at BeiGene in San Mateo, California, with extensive experience in clinical pharmacology and regulatory submissions.
Title
Ying Ou, PhD, holds the position of Executive Director at BeiGene, located in San Mateo, California, United States.
Current Role at BeiGene
Ying Ou, PhD, is currently serving as the Executive Director at BeiGene in San Mateo, California. In this role, Dr. Ou leverages extensive expertise in clinical pharmacology to guide strategic project decisions and oversee critical functions within the organization.
Previous Roles and Experience
Dr. Ou has held several notable positions prior to the current role at BeiGene. From 2017 to 2021, Dr. Ou was the Senior Director, Clinical Pharmacology at BeiGene in the San Francisco Bay Area. Prior to this, Dr. Ou worked at Onyx Pharmaceuticals / Amgen from 2013 to 2017 as Associate Director / Principal Scientist, at Theravance as Associate Director from 2010 to 2012, at Roche Pharmaceuticals Palo Alto as Principal Scientist from 2007 to 2010, and at ALZA / Johnson & Johnson as Senior Scientist from 2004 to 2007. Dr. Ou also served as a Pharmacokineticist at Human Genome Sciences from 2001 to 2003 and as a Postdoctoral Fellow at Colorado State University from 2000 to 2002.
Education and Expertise
Dr. Ying Ou attained a Doctor of Philosophy (Ph.D.) in Pharmacology and Toxicology from the University of Washington School of Medicine, completing the program in 1997 after seven years of study. Throughout an extensive career, Dr. Ou has developed a robust background in small molecules, protein, and antibody therapeutics. Key areas of expertise include the design and execution of preclinical DMPK and clinical PK/SAD/MAD/BA/BE/DDI clinical pharmacology studies, along with the development of mechanistic PBPK and population NONMEM models.
Regulatory and Leadership Experience
Dr. Ying Ou has a wealth of experience in regulatory submissions and approvals, including IND and NDA processes. Dr. Ou has engaged with major regulatory bodies such as the EMA and FDA to secure project clearances. Additionally, Dr. Ou brings significant management and leadership capabilities to the field of clinical pharmacology, contributing to project decisions and advancing organizational goals.